Heron flying lower after CRL

30 June 2020
heron-therapeuticsbig

US biotech Heron Therapeutics (Nasdaq: HRTX) was one of a number of companies to announce on Monday that it had received a complete response letter (CRL) from the US Food and Drug Administration (FDA).

The CRL relates to the company’s New Drug Application (NDA) for HTX-011 for the management of postoperative pain.

According to the letter, the FDA is unable to approve the NDA in its present form based on the need for additional non-clinical information. The agency did not identify any clinical safety or efficacy issues or CMC issues.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology